MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/bmj-2025-085457

Медицинская библиотека · BMJ (Clinical research ed.) · 2025

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.

Liu Yin, Gong Yue, Zhu Xiu-Zhi, Liu Guang-Yu, Yu Ke-Da, Yang Fan, Chen Li, He Min, Hu Zhen, Chen Can-Ming, Cao A-Yong, Li Jun-Jie, Hou Yi-Feng, Di Gen-Hong, Wu Jiong, Jiang Yi-Zhou, Fan Lei, Wang Zhong-Hua, Shao Zhi-Ming

СтатьяКлиническое исследование III фазыРандомизированное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

To evaluate the efficacy and safety of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without carboplatin as adjuvant therapy for patients with high risk, early stage, triple negative breast cancer.

DESIGN

Randomised, open label, phase 3 trial.

SETTING

Fudan University Shanghai Cancer Center in China between March 2020 and March 2022.

PARTICIPANTS

Female patients with operable high risk triple negative breast cancer (defined as either regional node positive or node negative with a Ki-67 labelling index of ≥50%) after definitive surgery.

INTERVENTIONS: Patients were randomised in a 1:1 ratio into either the carboplatin arm (four cycles of two weekly epirubicin and cyclophosphamide followed by four cycles of weekly paclitaxel combined with carboplatin) or the control arm (four cycles of three weekly or two weekly epirubicin and cyclophosphamide followed by four cycles of weekly paclitaxel).

MAIN OUTCOME MEASURES: The primary endpoint was disease-free survival in the intention-to-treat population. Secondary endpoints included recurrence-free survival, distant disease-free survival, overall survival, and safety.

RESULTS

Of the 808 enrolled patients, 807 received study treatment. At a median follow-up of 44.7 months, estimated percentages of patients who would be disease-free at three years were 92.3% in the carboplatin arm and 85.8% in the control arm (hazard ratio 0.64, 95% confidence interval (CI) 0.43 to 0.95; P=0.03). However, the assessment of the proportional hazards assumption showed that it was violated (P=0.02). A piecewise hazard model showed that the hazard ratio changed over time: the hazard ratio was 0.31 (95% CI 0.13 to 0.73) for 0-12 months, 0.65 (0.39 to 1.09) for 12-36 months, and 1.98 (0.69 to 5.69) for >36 months. For secondary endpoints, the carboplatin arm was associated with improved outcomes in three year recurrence-free survival (93.8% v 88.3%; hazard ratio 0.59, 95% CI 0.37 to 0.93; P=0.02), three year distant disease-free survival (94.8% v 89.8%; hazard ratio 0.61, 0.37 to 0.98; P=0.04), and three year overall survival (98.0% v 94.0%; hazard ratio 0.41, 0.20 to 0.83; P=0.01). The incidence of grade 3-4 treatment related adverse events was 66.7% (269 of 403 patients) in the carboplatin arm and 55.0% (222 of 404 patients) in the control arm. No treatment related deaths occurred.

CONCLUSIONS

The addition of carboplatin to adjuvant anthracycline/taxane based chemotherapy significantly improved survival outcomes in patients with high risk, early stage, triple negative breast cancer, driven by reduction of early recurrence risk without new safety concerns.

TRIAL REGISTRATION: ClinicalTrials.gov NCT04296175.

Для цитирования: Liu Yin, Gong Yue, Zhu Xiu-Zhi, Liu Guang-Yu, Yu Ke-Da, Yang Fan, Chen Li, He Min, Hu Zhen, Chen Can-Ming, Cao A-Yong, Li Jun-Jie, Hou Yi-Feng, Di Gen-Hong, Wu Jiong, Jiang Yi-Zhou, Fan Lei, Wang Zhong-Hua, Shao Zhi-Ming. Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.. BMJ (Clinical research ed.). 2025. DOI: 10.1136/bmj-2025-085457.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.